Lung Cancer
Latest News
Advertisement
Latest Videos
CME Content
Advertisement
More News
Following at least 3 years of follow-up, patients with advanced non-small cell lung cancer and tumor PD-L1 expression ≥ 1% or < 1% experienced durable and long-term efficacy benefits from frontline treatment with nivolumab plus ipilimumab, compared with chemotherapy.
Fam-trastuzumab deruxtecan-nxki demonstrated favorable clinical activity with a high objective response rate and durable responses in patients with HER2-mutated non–small cell lung cancer.
Melissa L. Johnson, MD, discusses the results of the phase 2 CITYSCAPE trial in PD-L1–positive non–small cell lung cancer (NSCLC).
Patients with chemotherapy-naïve, locally advanced or metastatic non–small cell lung cancer who were treated in the phase 2 CITYSCAPE trial with tiragolumab, an inhibitor of the immunomodulatory receptor TIGIT, plus and anti–PD-L1 agent demonstrated better efficacy versus single-agent checkpoint inhibitor therapy alone.
Adjuvant treatment with osimertinib demonstrated an 83% reduction in the risk of disease recurrence or death in patients with stage II to IIIA EGFR-mutant non–small cell lung cancer.
Atezolizumab in combination with carboplatin and etoposide has been approved in the UK for the frontline treatment of patients with extensive-stage small cell lung cancer.
The FDA has approved nivolumab combined with ipilimumab and chemotherapy for use as a frontline treatment for patients with metastatic or recurrent non–small cell lung cancer.
Nitika Thawani, MD, discusses identifying the difference between adverse events that are associated with radiation versus COVID-19 symptoms in lung cancer.
Anastasios (Tassos) Dimou, MD, shares advice from managing patients with non–small cell lung cancer who experience disease progression following therapy.
Future of NTRK Fusions
ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute
Challenges for TRK Fusion–Targeting Agents
ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute
Acquired Resistance in TRK Fusion-Positive Cancers
ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute
Approaching Treatment for TRK Fusion–Positive Cancers
ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute
TRK Inhibitor in GI Cancers: Adverse Effect Profile
ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute
Efficacy of TRK Inhibitors
ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute
Early Development of TRK Inhibitors
ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute
Advice for Interpreting NGS Reports
ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute
Driver Mutations in NTRK Fusion-Positive Cancers
ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute
Genomic Testing for NTRK Fusions in Lung and GI Cancers
ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute
Approaching Genomic Testing for NTRK Fusions
ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute
Using Molecular Testing in GI Cancers
ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute
Evolution of NGS Testing in Lung Cancers
ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute
Variants of NTRK Fusions in Solid Tumors
ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute
Role of NTRK Inhibitors
ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute
Ahead of the 2020 ASCO Virtual Scientific Program, we spoke with a handful of leading oncologists in breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, and hematologic malignancies to gain their perspectives on the most significant studies in their respective specialties.
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
5